SART3 and neoplasm: In contrast, other treatments (n = 5−6 in each group) with SART3 (3.9±0.6 g), GM-CSF (5.3±1.5 g), CD40L (5.7±2.7 g), CD40L+GM-CSF (4.3±3.5 g), SART3+GM-CSF (6.5±3.5 g), or SART3+CD40L (6.4±2.0 g) did not inhibit tumor growth.